CCRM Australia aims to build upon existing efforts to overcome industry challenges with established CCRM services and experience.

By engaging local regenerative medicine (RM) companies to be part of the CCRM industry consortium, we aim to raise the rates of success for collaboration and innovation within Australia and promote more opportunities to link Australian companies to international networks and expertise.

The industry consortium sponsorship and engagement model provides sponsors with increased access to CCRM expertise, market knowledge and networks of key opinion leaders.

Australian companies that access the network through CCRM Australia will also benefit from specialised local support provided by the Regenerative Medicine Industry Interface (RMI2) a consortium of local regenerative medicine industry participants, key academic and dedicated service providers and peak bodies. The consortium provides subsidised industry-focused research programs and initiatives that support the research and business objectives of the local regenerative medicine companies.

Joining the industry consortium offers industry members unparalleled opportunities and access to the global regenerative medicine network. The current industry consortium includes large multinationals, small-medium enterprises (SME) and emerging biotechnology companies in key sectors of regenerative medicine including, pharmaceutical, devices, reagents, tools, biomaterials and cell therapies.

Industry and other sponsors are invited to connect with other local and international industry participants through two levels of sponsorship, developed by agreement with CCRM.

These are $2,000 pa (supporting sponsorship) or $10,000pa (principal sponsorship).

Joining the CCRM industry consortium provides opportunities to realise on benefits appropriate to your organisation including increased visibility to a global network of world-leading regenerative medicine companies. It also includes business skills, leadership, funds for product development and receptor capacity for technologies and products.

As funds from Australia companies sponsorship will stay in Australia, it will help to support the local regenerative industry in Australia.

More information can be found at the website, https://ccrm.ca/regenerative-medicine-industry-consortium or by contacting Nicole Forgione, (Business Development Lead, Strategic Partnerships) at nicole.forgione@ccrm.ca.

Should you wish to know more information, please Nicole directly or Chih Wei Teng, CCRM Australia Industry Liaison Officer, at chihwei.teng@ccrmaustralia.com.au


 

Supporting Sponsorship

(a) Increased brand recognition and awareness:

  • Promotion through CCRM’s social media and marketing platforms by sharing and reposting publicly announced Company news and features in Signals blog posts and by-lined articles
  • Logo advertisement on CCRM’s website.

(b) Access to potential customers:

  • Priority invitation to speak, present or attend relevant CCRM organized events and workshops (e.g. iPSC Workshop, Cell & Gene Therapy Manufacturing in Clinical Trials Workshop, Till & McCulloch Meetings).

(c) Access to IP:

  • Priority access to promising intellectual property opportunities that are either disclosed to CCRM or generated by CCRM that are seeking a receptor or co-development; and
  • Engagement with CCRM and its network to help source specific IP of interest.

(d) Thought leadership and collaborative development and advancement of project ideas:

  • Engagement meetings with CCRM at least once per year with a focus on identifying and discussing potential collaborative opportunities around business, R&D, manufacturing, regulatory or large strategic projects;
  • Opportunity to propose topics for co-hosting webinars and co-publishing white papers
  • Preferred partner status for co-developing large strategic initiatives that leverage public or other funding and address gaps in the industry; and
  • Personalized annual report summarizing key engagement activities and outcomes
  • Regular updates on the exciting activities happening at CCRM, new technology IP available for licencing or co-development, and funding opportunities for collaborative and strategic initiatives.

(e) Increased engagement with the broader RM community:

  • Invitations to one or more CCRM sponsored industry networking receptions held at major RM meetings (e.g. ISCT, ISSCR, Phacilitate) each year; and
  • Invitation to the annual networking reception held at the Till & McCulloch Meeting, Canada’s premier stem cell and regenerative medicine research event.

Principal Sponsorship

(a) Increased brand recognition and awareness:

  • Automatic general sponsorship status at CCRM organized events and workshops (e.g. Till & McCulloch Meetings, iPSC Workshop, Cell & Gene Therapy Manufacturing in Clinical Trials Workshop);
  • Discount on higher tier sponsorship of the Till & McCulloch Meetings, Canada’s premier stem cell and regenerative medicine research event: up to 5% for <$10,000 sponsorship spend (maximum $500 discount) and 10% on a sponsorship spend of $10,000 to $25,000 ($1,000 to $2,500 discount);
  • Logo promotion on prominently displayed signage in the office of CCRM’s new 40,000 ft2 facility (opening at the MaRS facility in Toronto’s Discovery District planned for late 2016), whereover 1,000 local and international visitors are expected each year;
  • Logo advertisement in CCRM presentations that are delivered in over 100 speaking engagements each year, with thousands in attendance;
  • Logo advertisement in CCRM’s annual report;
  • Logo advertisement on CCRM’s website;
  • Opportunity to be featured in a spotlight article in CCRM’s annual report;
  • Opportunity to be highlighted in CCRM’s monthly newsletter, which has a viewership of 1,500 RM professionals from around the world;
  • Advertisement of videos with educational content on CCRM’s RM Network video channel once per year on topics to be agreed upon and approved by CCRM; and
  • Promotion through CCRM’s social media and marketing platforms by sharing and reposting publicly announced Company news and features in Signals blog posts and by-lined articles.

(b) Access to potential customers:

  •  Priority invitation to speak, present or attend relevant CCRM sponsored events (e.g. iPSC Workshop, Cell & Gene Therapy Manufacturing in Clinical Trials Workshop).

(c) Access to IP:

  • Priority access to promising intellectual property opportunities that are either disclosed to CCRM orgenerated by CCRM that are seeking a receptor or co-development; and
  • Engagement with CCRM and its network to help source specific IP of interest.

(d) Thought leadership and collaborative development and advancement of project ideas:

  • Engagement meetings with CCRM at least once per year with a focus on identifying and discussing potential collaborative opportunities around business, R&D, manufacturing, regulatory or large strategic projects;
  • Opportunity to propose topics for co-hosting webinars and co-publishing white papers;
  • Preferred partner status for co-developing large strategic initiatives that leverage public or other funding and address gaps in the industry;
  • Personalized annual engagement report summarizing key engagement activities and outcomes; and
  • Regular updates on the activities happening at CCRM, new technology IP available for licencing or codevelopment, and funding opportunities for collaborative and strategic initiatives.

(e) Increased engagement with the broader RM community:

  • Invitations to one or more CCRM sponsored industry networking receptions held at major RM meetings (e.g. ISCT, ISSCR, Phacilitate) each year;
  • One complimentary registration to attend the Till & McCulloch Meetings, which provides Companies with access to key opinion leaders in academia, highly skilled graduate students and potential customers; and
  • Invitation to the annual Till & McCulloch networking reception.